The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.
Michel Delforge
Consultant or Advisory Role - Celgene; Janssen-Cilag
Leonard Minuk
Honoraria - Celgene; Janssen-Ortho
Research Funding - Bristol-Myers Squibb; Celgene; Onyx
Jean-Claude Eisenmann
No relevant relationships to disclose
Bertrand Arnulf
No relevant relationships to disclose
Letizia Canepa
No relevant relationships to disclose
Alberto Fragasso
No relevant relationships to disclose
Serge Leyvraz
No relevant relationships to disclose
Christian Langer
Honoraria - Celgene; Janssen-Cilag
Research Funding - Celgene
Yousef Ezaydi
No relevant relationships to disclose
Dan T. Vogl
Consultant or Advisory Role - Celgene
Pilar Giraldo-Castellano
No relevant relationships to disclose
Sung-Soo Yoon
No relevant relationships to disclose
Angelo Martins
No relevant relationships to disclose
Charles Zarnitsky
Honoraria - Celgene
Research Funding - Celgene
Martine Escoffre Barbe
No relevant relationships to disclose
Bernard Lemieux
Honoraria - Celgene
Research Funding - Celgene
Irina Proskorovsky
Research Funding - Celgene
Annette L. Ervin-Haynes
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Vanessa Houck
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Thierry Facon
Consultant or Advisory Role - Celgene